Sanofi News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

23.02.24	Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report (EN, Sanofi-Aventis)
23.02.24	Sanofi: Dupixent SBLA Accepted For FDA Priority Review For COPD With Type 2 Inflammation (RTTNews)
23.02.24	Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation (EN, Sanofi-Aventis)
23.02.24	Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation (GlobeNewswire)
22.02.24	Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors (GlobeNewswire)
22.02.24	Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors (EN, Sanofi-Aventis)
20.02.24	Sanofi: Information concerning the total number of voting rights and shares - January 2024 (GlobeNewswire)
20.02.24	Private Equity Firms Show Interest In Sanofi's Consumer Health Unit: Bloomberg (RTTNews)
16.02.24	Sanofi's Dupixent Approved In Japan For Chronic Spontaneous Urticaria Treatment (RTTNews)
16.02.24	Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU) (EN, Sanofi-Aventis)
16.02.24	Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU) (GlobeNewswire)
15.02.24	Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS (GlobeNewswire)
15.02.24	Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS (EN, Sanofi-Aventis)
09.02.24	Media Update: New data presented at AAAAI highlight Sanofi’s scientific leadership across inflammatory diseases (EN, Sanofi-Aventis)
06.02.24	Media Update: New data demonstrate clinical safety, benefit and durability of Nexviazyme® across a wide-range of Pompe disease patient groups (EN, Sanofi-Aventis)
05.02.24	Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses (EN, Sanofi-Aventis)
05.02.24	Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses (GlobeNewswire)
01.02.24	Sanofi Posts Q4 Loss, Sees Stable FY24 Business EPS; Names Nestle's Francois-Xavier Roger CFO (RTTNews)
01.02.24	Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee (EN, Sanofi-Aventis)
01.02.24	Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline (GlobeNewswire)
01.02.24	Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline (EN, Sanofi-Aventis)
01.02.24	Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee (GlobeNewswire)
25.01.24	Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) (EN, Sanofi-Aventis)
25.01.24	Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) (GlobeNewswire)
23.01.24	Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline (EN, Sanofi-Aventis)
23.01.24	Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline (GlobeNewswire)
17.01.24	Sanofi: Information concerning the total number of voting rights and shares - December 2023 (GlobeNewswire)
16.01.24	Media Update: Dupixent® (dupilumab) U.S. label updated with data further supporting use in atopic dermatitis with moderate-to-severe hand and foot involvement (EN, Sanofi-Aventis)
09.01.24	Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee (EN, Sanofi-Aventis)
09.01.24	Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee (GlobeNewswire)
28.12.23	Biotech Stocks Facing FDA Decision In January 2024 (RTTNews)
21.12.23	Sanofi To Discontinue Development Program Of Tusamitamab Ravtansine As CARMEN-LC03 Trial Fails (RTTNews)
21.12.23	Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint (GlobeNewswire)
21.12.23	Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint (EN, Sanofi-Aventis)
18.12.23	Sanofi: Information concerning the total number of voting rights and shares - November 2023 (GlobeNewswire)
15.12.23	Press Release: Availability of the Q4 2023 Memorandum for modelling purposes (GlobeNewswire)
15.12.23	Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa (GlobeNewswire)
12.12.23	Sanofi Terminates Pompe Disease Drug Agreement With Maze Therapeutics Following FTC Opposition (RTTNews)
11.12.23	Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics (GlobeNewswire)
11.12.23	Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone (GlobeNewswire)
07.12.23	Sanofi: Sarclisa Phase 3 Trial Meets Primary Endpoint Of Progression Free Survival (RTTNews)
07.12.23	Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant (GlobeNewswire)
07.12.23	Sanofi Says Developing 12 Experimental Medicines (RTTNews)
07.12.23	Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology (GlobeNewswire)
27.11.23	Sanofi Posts Positive NOTUS Trial Result Of Dupixent In COPD (RTTNews)
27.11.23	Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this seri (GlobeNewswire)
23.11.23	Sanofi: Information concerning the total number of voting rights and shares - October 2023 (GlobeNewswire)
30.10.23	MeiraGTx Says Sanofi Acquired 4 Mln Shares For $30 Mln; MeiraGTx Up In Pre-market (RTTNews)
27.10.23	Sanofi Q3 Profit Rises, Backs FY23 View, To Split Consumer Healthcare Unit; Stock Dips (RTTNews)
27.10.23	Sanofi Q3 Profit Rises; To Separate Consumer Healthcare Business (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		SPI-Handel aktuell: SPI zum Handelsende leichter
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter
20.12.24		Handel in Europa: STOXX 50 schliesst im Minus
20.12.24		Schwacher Handel: SMI schliesst mit Verlusten